STOCK TITAN

Brickell Biotech Inc - BBI STOCK NEWS

Welcome to our dedicated news page for Brickell Biotech (Ticker: BBI), a resource for investors and traders seeking the latest updates and insights on Brickell Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Brickell Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Brickell Biotech's position in the market.

Rhea-AI Summary
Fresh Tracks Therapeutics, Inc. (Nasdaq: FRTX) has adjourned its special meeting of stockholders to December 15, 2023, to seek approval for liquidation and dissolution. If not approved, the company intends to seek judicial dissolution, potentially reducing cash distributable to stockholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Fresh Tracks Therapeutics, Inc. (Nasdaq: FRTX) Announces Adjournment of Special Meeting and Urges Stockholders to Vote on Liquidation and Dissolution Plan
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.74%
Tags
none
-
Rhea-AI Summary
Fresh Tracks Therapeutics, Inc. (Nasdaq: FRTX) announced a plan of liquidation and dissolution after a strategic evaluation process. The company aims to distribute between $5 million and $7 million, or $0.84 to $1.17 per share, to stockholders if the dissolution is approved at the special meeting on November 16, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
Rhea-AI Summary
Fresh Tracks Therapeutics, Inc. plans to distribute cash to shareholders between $5 million and $7 million, or $0.84 to $1.17 per share, following shareholder approval and the filing of the certificate of dissolution. The company is discontinuing all clinical and preclinical development programs and reducing its workforce, except for certain employees involved in the dissolution process. The board of directors unanimously concluded that dissolving and liquidating the company is in the best interests of shareholders. The company intends to hold a special meeting of shareholders in Q4 2023 to seek approval for the liquidation and dissolution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
55.17%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Fresh Tracks Therapeutics strengthens cash position by selling rights to future milestone and earnout payments to Botanix SB Inc. for $8.25 million. The agreement is seen as a win-win deal and provides non-equity-dilutive capital. Fresh Tracks continues to evaluate strategic options to maximize shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
39.71%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.77%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
management
Brickell Biotech Inc

Nasdaq:BBI

BBI Rankings

BBI Stock Data

6.75M
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Boulder

About BBI

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell's executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell's strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs.